Health-care companies rose as traders continued to rotate out of high-risk artificial-intelligence stocks into lagging sectors.
Shares of Moderna added to recent gains amid optimism the vaccine maker's efforts to diversify its offerings would bear fruit.
Roche Holding said a drug candidate showed better potential than existing therapies in a late-stage study with patients with a type of advanced lung cancer who had been previously treated.
Abivax shares added to recent gains after the French biotechnology company increased the size of a stock offering, signaling investor appetite in the wake of positive clinical-trial data.
Recent Abivax data on an ulcerative colitis product candidate showed promise, said analysts at brokerage Stifel.
